Remedy Plan Therapeutics Appoints Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer [Yahoo! Finance]
ImageneBio, Inc. (IMA)
Company Research
Source: Yahoo! Finance
company developing novel therapies that target fundamental metabolic vulnerabilities in disease, today announced the appointment of Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer (CFO & CBO). “Joti brings a strong blend of corporate leadership, financial insight, strategic creativity, and all- around deep experience in the biotechnology sector,” said Greg Crimmins, Ph.D., Founder and Chief Executive Officer of Remedy Plan Therapeutics. “As we enter our next phase of growth, Joti will be instrumental in strengthening our financial position, advancing our corporate goals, and expanding our relationships with the investment community and strategic partners.” Dr. Marango brings to Remedy Plan Therapeutics more than 15 years of experience across biotechnology, business development, corporate strategy, and public markets. He most recently served as Chief Operating Officer and Chief Financial Officer at Ikena Oncology, a company focused on small molecule design and d
Show less
Read more
Impact Snapshot
Event Time:
IMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMA alerts
High impacting ImageneBio, Inc. news events
Weekly update
A roundup of the hottest topics
IMA
News
- ImageneBio Announces $30 Million Private PlacementGlobeNewswire
- ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- ImageneBio (IMA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "strong sell" toMarketBeat
- ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company UpdateGlobeNewswire
IMA
Sec Filings
- 4/16/26 - Form 3
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- IMA's page on the SEC website